By Fineline Cube Shenzhen Salubris Pharmaceuticals Co., Ltd. (SHE: 002294) announced market approval from China’s National Medical Products Administration (NMPA) for Xinfutai Plus (teriparatide), a novel once-weekly formulation indicated for the treatment of osteoporosis in postmenopausal women at high risk of fracture.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Full marketing authorization |
| Product | Xinfutai Plus (teriparatide, once-weekly formulation) |
| Indication | Osteoporosis in postmenopausal women at high risk of fracture |
| Approval Date | 18 May 2026 |
| Market Status | First and only once-weekly teriparatide formulation approved in China |
Product Profile & Innovation
- Molecule: Teriparatide (recombinant human parathyroid hormone 1-34)
- Formulation: Extended-release, once-weekly subcutaneous injection
- Innovation: First weekly dosing regimen for teriparatide in China, addressing adherence challenges associated with daily injections
- Differentiation: No competing products with identical specification or dosing regimen currently marketed in China
Market Context & Competitive Position
Osteoporosis affects approximately 70 million people in China, with postmenopausal women representing the largest patient segment. Current treatment options include daily teriparatide injections, which often suffer from poor long-term adherence due to injection burden.
Salubris’ strategic advantages include:
- Established market presence through Xinfutai Pro (once-daily liquid teriparatide formulation)
- Strong brand recognition in China’s bone formation promoter segment
- Comprehensive osteoporosis portfolio spanning different administration frequencies
- Potential to capture patients seeking improved convenience without switching therapeutic classes
Commercial Outlook
- Pricing Strategy: Expected premium pricing versus daily formulations, reflecting improved convenience and adherence benefits
- Market Penetration: Initial focus on tier-1 and tier-2 cities with specialized osteoporosis clinics and endocrinology centers
- Revenue Impact: Projected to contribute significantly to Salubris’ bone health segment, which generated ¥850 million ($120 million) in 2025
- Reimbursement Status: Anticipated inclusion in provincial reimbursement lists within 6-12 months post-launch
Strategic Implications
- Portfolio Expansion: Xinfutai Plus complements existing Xinfutai Pro, enabling Salubris to address diverse patient preferences and clinical scenarios
- Market Leadership: Reinforces Salubris’ position as China’s leading provider of bone formation therapies
- International Potential: Success in the domestic market may support future regulatory filings in other Asian markets
- R&D Validation: Demonstrates Salubris’ capabilities in advanced drug delivery technologies and formulation development
Forward‑Looking Statements
This brief contains forward-looking statements regarding market approval, commercial performance, and strategic positioning for Xinfutai Plus. Actual results may differ due to risks including market adoption rates, reimbursement decisions, and competitive dynamics.-Fineline Info & Tech